ANAB
AnaptysBio IncNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$1.90B
P/E Ratio
—
EPS
$-0.46
Beta
0.41
52W High
$71.67
52W Low
$11.40
50-Day MA
$42.95
200-Day MA
$28.11
Dividend Yield
—
Profit Margin
-5.64%
Forward P/E
—
PEG Ratio
0.00
About AnaptysBio Inc
AnaptysBio, Inc., a clinical-stage biotechnology company, is dedicated to developing therapeutic product candidates for inflammation and immuno-oncology indications. The company is headquartered in San Diego, California.
Fundamentals
| Revenue (TTM) | $234.60M |
| Gross Profit (TTM) | $98.63M |
| EBITDA | $48.45M |
| Operating Margin | 61.80% |
| Return on Equity | -24.50% |
| Return on Assets | 7.06% |
| Revenue/Share (TTM) | $8.16 |
| Book Value | $1.33 |
| Price-to-Book | 51.08 |
| Price-to-Sales (TTM) | 8.10 |
| EV/Revenue | 6.83 |
| EV/EBITDA | 23.15 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 151.10% |
| Shares Outstanding | $28.75M |
| Float | $17.26M |
| % Insiders | 5.86% |
| % Institutions | 101.04% |
Historical Volatility
HV 10-Day
114.09%
HV 20-Day
87.34%
HV 30-Day
87.74%
HV 60-Day
76.88%
HV Rank
88.1%
Volatility is currently expanding
Analyst Ratings
Consensus ($77.33 target)
3
Strong Buy9
Buy1
HoldData last updated: 4/29/2026